Roche ’s Gazyva (obinutuzumab) delivers positive topline results for phase II lupus nephritis study

Roche today announced positive topline results for NOBILITY, a phase II clinical trial investigating the safety and efficacy of Gazyva ® (obinutuzumab) for adults with proliferative lupus nephritis.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news